Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients ≥ 18 years of age~* An acute onset of at least 3 of the following signs and symptoms (new or worsening):~  1. Cough~ 2. Production of purulent sputum~ 3. Shortness of breath (dyspnea)~ 4. Chest pain due to pneumonia~* At least 1 of the following:~  1. Fever~ 2. Hypothermia~ 3. Presence of pulmonary rales and/or evidence of pulmonary consolidation~* PORT Risk Class II, III, or IV~* Presence of lobar, multilobar, or patchy parenchymal infiltrate(s) consistent with acute bacterial pneumonia on a pulmonary imaging study~* Not received any systemic antibiotics during the prior 7 days~Exclusion Criteria:~* Ventilator-associated pneumonia~* Known anatomical or pathological bronchial obstruction or a history of bronchiectasis or documented severe chronic obstructive pulmonary disease~* Hospitalization within 90 days or residence in a long-term care facility within 30 days prior to the onset of symptoms~* Presence of known:~  1. Viral or fungal pneumonia~ 2. Pneumocystis jiroveci pneumonia~ 3. Aspiration pneumonia~ 4. Other non-infectious causes of pulmonary infiltrates (e.g. pulmonary embolism, hypersensitivity pneumonia, congestive heart failure)~ 5. Primary or metastatic lung cancer~ 6. Cystic fibrosis~ 7. Active or suspected tuberculosis~* Known HIV or myasthesia gravis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solithromycin (Type: EXPERIMENTAL): Solithromycin 800 mg orally (PO) on Day 1 followed by 400 mg PO daily on Days 2 through 5, followed by placebo on Days 6 and 7
- Moxifloxacin (Type: ACTIVE_COMPARATOR): Moxifloxacin 400 mg PO daily on Day 1 through Day 7

Based on this trial design, predict the completion outcome and termination type (if applicable).